ArticleHealth services research2025

Drivers of infliximab biosimilar uptake: A comparative analysis of new biosimilar initiations versus switching in a national rheumatology registry.

Eric Thomas Roberts et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.